- Preparation of phosphorus-nitrogen flame retardant and application of phosphorus-nitrogen flame retardant in anti-aging flame-retardant composite material
-
The invention discloses preparation of a phosphorus-nitrogen type flame retardant and application of the phosphorus-nitrogen type flame retardant in an anti-aging flame-retardant composite material. The preparation comprises the following steps: mixing creatine monohydrate, urea and a phosphoric acid solution, carrying out oil bath stirring reaction, and naturally conducting cooling to room temperature to obtain a reacted solution; and pouring the reacted solution into absolute ethyl alcohol to generate a flocculent product, carrying out centrifugal washing for multiple times, and conducting drying to obtain the phosphorus-nitrogen type flame retardant. The anti-aging flame-retardant composite material is prepared according to the following steps: dissolving polyvinyl alcohol in deionized water to obtain a polyvinyl alcohol solution; mixing fluorescent powder, creatine monohydrate and a polyvinyl alcohol solution, and uniformly conducting stirring to obtain a dispersion system; and conducting drying at room temperature to prepare the aging-resistant flame-retardant polyvinyl alcohol composite material. The preparation method has the advantages of cheap raw materials and simple process, and is suitable for large-scale industrial production. The prepared aging-resistant flame-retardant polyvinyl alcohol composite material does not change the transparency of the original polyvinyl alcohol, and can be widely applied to the field of decoration.
- -
-
Paragraph 0022; 0024; 0026
(2021/08/07)
-
- Synthesis technology of creatine phosphate sodium
-
The invention provides a synthesis technology of creatine phosphate sodium. The technology comprises the following steps: reacting creatine monohydrate with phosphoric acid in ethanol to obtain ethanol-insoluble creatine phosphate; and carrying out a refluxing reaction on the creatine phosphate in an ethyl acetate solvent with 4-dimethylpyridine (DMAP) as a creatine phosphorylation reaction catalyst and dicyclohexylcarbodiimide (DCC) as a reaction dehydrant to obtain phosphorylated creatine, carrying out alkaline hydrolysis on the phosphorylated creatine in an aqueous solution of sodium hydroxide, filtering the obtained alkaline hydrolysis product, and adding ethanol to the obtained filtrate to obtain the creatine phosphate sodium. The whole technology is a normal-temperature and normal-pressure technology basically, and has the advantages of low energy consumption and high single-step reaction yield. Water-insoluble 1,3-dicyclohexylurea (DCU) completely formed by the DCC dehydrant in the alkaline hydrolysis workshop section can be filtered out, and the ethanol is directly added to the aqueous solution to precipitate a high-quality creatine phosphate disodium salt. The ethyl acetate and anhydrous ethanol used in the technology can be recycled. The discharge capacity of wastewater in the whole technology is small.
- -
-
Paragraph 0061; 0062; 0064
(2018/03/01)
-
- Creatine phosphate prodrugs, compositions and uses thereof
-
Membrane permeable prodrugs of creatine phosphate, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate or pharmaceutical compositions thereof are disclosed.
- -
-
Page/Page column 57
(2010/11/29)
-
- Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
-
A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.
- -
-
-
- Carotenoid analogs or derivatives for controlling C-reactive protein levels
-
A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.
- -
-
-
- Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
-
A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.
- -
-
-
- Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
-
A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.
- -
-
-
- Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
-
A method of treating liver disease in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.
- -
-
-
- Carotenoid analogs or derivatives for the inhibition and amelioration of disease
-
A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a chemical compound including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.
- -
-
-
- Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
-
A method of treating ischemic reperfusion injury in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.
- -
-
-
- Carotenoid ether analogs or derivatives for controlling connexin 43 expression
-
A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.
- -
-
-
- Synthesis of Methoxycarbonyl Phosphate, a New Reagent Having High Phosphoryl Donor Potential for Use in ATP Cofactor Regeneration
-
Reaction of an aqueous solution of phosphate ion (pH 7.8) with acetic anhydride in a two-phase system gives acetyl phosphate.Reaction of phosphate with methyl chloroformate yields methoxycarbonyl phosphate.Both reagents are useful for in situ regeneration of ATP from ADP in organic synthetic procedures based on enzyme-catalyzed reactions requiring ATP.Acetyl phosphate has been used for this purpose previously; methoxycarbonyl phosphate is a new compound, and its use in ATP regeneration is also new.The characteristics of methoxycarbonyl phosphate which makes it interesting are its ease of preparation, its acceptability as a substrate for both acetate kinase and carbamate kinase, and its high phosphoryl donor potential.It has the additional attractive feature that the product remaining after phosphoryl transfer, methyl carbonate, decomposes spontaneusly in solution and forms methanol and carbon dioxide.These products present no difficulties in workup and avoid the problem of product inhibition which is sometimes troublesome in regeneration schemes based on acetyl phosphate or phosphoenolpyruvate.The principal disadvantage of methoxycarbonyl phosphate as a phosphorylating reagent in ATP regeneration, relative to acetyl phosphate, is that it decomposes inconveniently rapidly under the conditions used for enzymatic synthesis (t1/2 = 0.3 h at 25 deg C, pH 7).
- Kazlauskas, Romas J.,Whitesides, George M.
-
p. 1069 - 1076
(2007/10/02)
-
